The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

Disease-Modifying Therapy Comparison and Side Effects ...

Brenig has launched an early Phase 1 trial to evaluate BT-409, its experimental small molecule therapy, in healthy volunteers ...

Medically reviewed by Lindsay Cook, PharmD Key Takeaways MS medications can help slow the disease and manage symptoms.

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...

A brain protein called ANO2 has emerged as a new piece of the puzzle linking Epstein-Barr virus (EBV) infections and MS ...

Nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received at least one pharma industry payment, with higher volume prescribers more likely to be beneficiaries, finds a 5 ...

Quantum BioPharma Ltd. announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its drug Lucid-21-302 (Lucid-MS), aimed at treating Multiple Sclerosis (MS). This ...

Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on ...

An international research team has demonstrated that a new plant-derived drug can block the progression of multiple sclerosis (MS). University of Queensland researcher Dr Christian Gruber said the ...